BioSpace News Archive

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter ended September 29, 2023 on Wednesday, November 1, 2023 after the market close.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference® (FC23), taking place Oct. 19-22, 2023, in Las Vegas.

VitaTek, the only vertically integrated medical device incubator, accelerator, and manufacturer, is thrilled to announce the launch of a Series A Funding round with the goal to raise $50 million.

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.

Abivax SA (Euronext Paris: FR0012333284 - ABVX) (“Abivax” or the “Company”) today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares.

Ultragenyx Pharmaceutical Inc. announced the pricing of its underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share.

Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Y-mAbs Therapeutics, Inc. announced that its Board of Directors has appointed Michael Rossi as President and Chief Executive Officer and a member of the Board of Directors with an expected start date of November 6, 2023.

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at the following upcoming scientific conferences.